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Mio, and, other causes‘ (18-39 year old patients) with €33.80 Mio. CONCLUSIONS: A
multitude of causes for blindness affects primarily older people. Demographic de-
velopment will lead to an increase in blind people and therefore to a costly public
health problem. Loosing eyesight is connected to high cost on the one hand and to
a lower QOL for patients on the other hand. The analysis shows the high cost of
blindness for the whole society in Austria.
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OBJECTIVES: Blindness represents significant burden of disease worldwide. The
aim of this research is to estimate medical and non medical expenses related to
blindness of elderly patients (60 years) in Hungary so that results can be used for
further policy analyses. METHODS: Inputs for burden of disesase model were de-
rived from the published literature, statistical databases and structured interviews
with relevant experts. We divided the burden of elderly blindness into public and
private medical and non medical costs. In addition to direct costs (social care and
subvention, conduct recourse, medical costs) indirect costs and lost revenues (un-
employment, support to activities of daily living) were also calculated. RESULTS:
The social burden of 6051 elderly blind patients was estimated 53.35 million USD in
2009, 0.03% of the Hungarian GDP (1 USD 128.19 HUF in purchasing power parity
exchange rate). Social care and subventions (20.04 million USD), support to daily
living activities (15.91 million USD) and healthcare costs (6.68 million USD) repre-
sented the largest proportion of expenses. 55% of total burden were derived from
public sector and within public burden social care and subventions represented
two-third of expenses. CONCLUSIONS: The societal burden of elderly blindness is
significant even without measuring its impact on mortality and quality of life. It is
important to redefine the necessary health and social policy objectives of preven-
tion, health care and social integration of elderly blindness. Further research is
needed to measure the impact of medical and non-medical interventions to reduce
the societal burden of elderly blindness
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OBJECTIVES: Retina disease (RD) is a leading cause of blindness in Europe with
significant clinical and economic consequences. The research objective was to
assess the direct health care resource use of patients receiving regular intravitreal
injections (rIVI) to treat RD in France, Spain and the UK (UK). METHODS: Three
focus group sessions were performed with at least 6 retina specialists who treated
RD patients with rIVIs (defined as IVIs every 4 to 6 weeks). A specific questionnaire
assessed resource use including medical visits, diagnostic/monitoring tests and
procedures, drugs administered, IVI adverse event treatment, surgery and trans-
port. Costs were quantified using official and bibliographical sources from each
national health care system perspective over a one-year time horizon. All costs are
expressed in 2010 euros and pound sterling. RESULTS: The annual total direct
health care cost per patient treated with rIVI was €14,725 in France, €10,027 in Spain
and £9,647 to £13,759 in the UK (depending on the setting of care: outpatient or day
case). In all countries, pharmacological costs accounted for the largest proportion
of overall costs (50-80%). Ranibizumab was the most used drug except some coun-
tries that reported off-label use of bevacizumab. Non-pharmacological costs, in-
cluding follow-up visits, tests and administration costs, were €2353, €2918 and
£3000-£9096 in France, Spain and the UK, respectively. CONCLUSIONS: Treatment
with rIVIs is costly to health care systems. While drug costs account for a large
portion of costs, required monitoring is a key cost driver and affects health care
systems’ capacity to treat RD patients. Any strategy to reduce the number of rIVIs
per year would assist in reducing the burden on health care systems. Furthermore,
to assess the full cost of treatment, a study assessing direct cost to patients and
caregivers and indirect cost is also needed.
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OBJECTIVES:Ocular hypertension (OHT) and primary open-angle glaucoma (POAG)
are chronic eye conditions that progress over time, potentially leading to blindness.
Glaucoma management costs increase with disease severity and treatment
switches, drugs and surgical treatments being cost drivers. Our study aimed to
estimate this glaucoma management costs as a function of the disease stage and
the number of treatment changes in Germany. METHODS: We analyzed patient-
level data from an observational study with retrospective collection of medical
resources used by German glaucoma patients over a 5-year period. Associated
costs were derived for drug treatment, medical/surgical procedures, exams/tests
and hospitalizations (Statutory Health Insurance, 2009 costs). A linear regression
was performed on the total management costs and drug costs, with two indepen-
dent variables: the current disease stage (OHT [reference], early, moderate, ad-
vanced POAG), and the number of treatment changes (0 [reference], 1, 2, 3
changes). Costs were estimated against the reference category (OHT-No change).
RESULTS: Data from 154 OHT/POAG patients (57% female, mean age 67 /11
years) was analyzed. OHT patients without treatment change had a mean (SD) total
management cost of €123 (121) per year, which increased by €71 (p0.05), €153
(p0.05) and €398 (p0.004) in disease stages early, moderate and advanced POAG
respectively. Each treatment line change (1, 2, 3) also resulted in increase in cost
of €45 (p0.05), €177 (p0.05) and €451 (p0.0001) compared to the reference cost,
respectively. The drug cost followed the same pattern, with a mean (SD) reference
cost of €83 (33) per year and increases by €70 (p0.05), €88 (p0.022) and €160
(p0.0001) with the disease stage, and €22 (p0.05), €76 (p0.044) and €146
(p0.0001) with each treatment change. CONCLUSIONS: The analysis of observa-
tional data showed a significant increase of the glaucoma management costs with
both the disease severity and the number of treatment changes.
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OBJECTIVES: To estimate the mean annual cost of the different biological agents
licensed for the treatment of patients with moderate to severe plaque psoriasis
during the first year of treatment and maintenance, according to the daily clinical
practice in Spain. METHODS: Data were obtained from case notes of a sequential
patient cohort with psoriasis attending a tertiary referral severe psoriasis service
and initiated on biologics for treatment of their psoriasis at least 12 months before
to the cut-off date (November 2010). Data on drug usage (dose and dosage, starting
and changing dates), that patients have experienced throughout the treatment,
were collected To estimate the annual drug cost for each patient, two periods of
time were considered in the analysis: first year after initiation of biologic therapy
and the year before the cut-off as maintenance period. Specific assumptions re-
garding the dosage, interruption, or switching to other biological after initiation of
treatment were set out. Only the cost of biological agents was considered, regard-
less of any other associated expenses, dismissing those subjects who have been on
therapy less than 3 months before switching to other biological drug.RESULTS:The
primary analysis population comprised a total of 760 patients: adalimumab
(n212), etanercept (n214), infliximab (n145), and ustekinumab (n189). These
subgroups were comparable in age, gender, weight, type of psoriasis, severity, joint
affectation and concomitant diseases prevalence. The mean annual costs were: for
adalimumab 13,346.48 € and 12,120.09 €, etanercept 15,268.28 € and 14,420.46 €,
infliximab 16,589.67€ and 13,889.49 €, and ustekinumab 18.370,50 € and 15.500,44 €.
CONCLUSIONS: The current cost analysis clearly shows that the expenditure as-
sociated with the use of adalimumab both, at the initiation of therapy and main-
tenance, reflects the lowest price charged for a biological drug in patients with
moderate to severe plaque psoriasis, in daily clinical practice in Spain.
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OBJECTIVES: The aim of the study was to analyse and estimate health-related
quality of life (HRQoL), costs of psoriasis during 12 months and disease severity
among patients with psoriasis in Denmark who had received different types of
treatment. METHODS: The study is based on 131 patients included from three
dermatology clinics and data from two different sources; a patient survey and a
retrospective chart review. Information about HRQoL (EQ-5D AND EQ-VAS), Der-
matology Life Quality Index (DLQI), disease severity, resource utilisation in health
care and productivity losses was collected from patient questionnaires. Patient
characteristics and type of treatment were collected from patient records.
RESULTS:During the study period, 16% of the patients used only emollients and/or
topical corticosteroids and 31% used systemic treatment (not biological drugs).
During part of or during the whole 12 months period 53% received biological treat-
ment. Mean direct cost per patient related to in- and out-patient care was esti-
mated to DKK10,682, and indirect cost was DKK9,668. Cost for drugs was DKK88,534
and cost for light treatment was DKK3,775 per patient. Indirect costs were
DKK4,300 for patients with no or minor psoriasis problems and DKK22,000 for
patients with moderate to very severe problems. Light treatment and hospitalisa-
tion costs made up the greatest part in patients receiving local topical treatment.
These costs were also higher in the topical group than in all other treatment
groups. The mean QoL values for all patients were: EQ-5D 0.76, EQ-VAS 74, and DLQI
5.0. The latter value corresponds to “small effect on patient’s life”. Fewer patients
treated with biological drugs experienced problems with treatment than other
treatment groups. CONCLUSIONS: Patients with more extensive psoriasis prob-
lems experienced lower QoL and a larger disease burden. Indirect costs increased
with disease severity. Costs increased with the use of more potent drugs (biological
and systemic drugs).
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